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tTATE-OF-THE-ART PAPER669The Role of CD40/CD40 Ligand in Atherothrombosisharalambos Antoniades, Constantinos Bakogiannis, Dimitris Tousoulis, Alexios S. Antonopoulos,
hristodoulos Stefanadis
ntoniades and colleagues review the evidence linking the CD40/CD40 ligand (CD40L)
ystem to cardiovascular risk, which is currently a topic of intensive research. CD40L and the
oluble form of the receptor, sCD40L, belong to the tumor necrosis factor superfamily and
re both prothrombotic and proinflammatory. sCD40L has multiple autocrine, paracrine, and
ndocrine actions, and it may trigger key mechanisms precipitating atherothrombosis. While
everal conventional cardiovascular medications, such as antiplatelet therapy, statins, and
ngiotensin-converting enzyme inhibitors, reduce sCD40L, it is unclear if agents designed
pecifically to target CD40/CD40L will reduce cardiovascular risk.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY
678rasugrel Improves Outcomes Over Clopidogrel
Regardless of Glycoprotein IIb/IIIa Inhibitor Useichelle O’Donoghue, Elliott M. Antman, Eugene Braunwald, Sabina A. Murphy, P. Gabriel Steg,
riel Finkelstein, William F. Penny, Viliam Fridrich, Carolyn H. McCabe, Marc S. Sabatine,
tephen D. Wiviott
rasugrel is a rapidly-acting thienopyridine that reduces ischemic events compared with
lopidogrel in patients with acute coronary syndromes undergoing percutaneous intervention,
lthough with increased bleeding. This subgroup analysis evaluated the impact of concomitant
se of a glycoprotein (GP) IIb/IIIa inhibitor. Approximately one-half of the subjects in the
RITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing
latelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) trial received a
P IIb/IIIa inhibitor, based on physician discretion. Prasugrel significantly reduced the risk
f ischemic events irrespective of GP IIb/IIIa inhibitor use. Prasugrel did increase the
leeding risk compared to clopidogrel, but combined treatment with a GP IIb/IIIa did not
lter the relative increased risk of bleeding. The use of GP IIb/IIIa inhibitors does not alter
he relative risks or benefits of prasugrel compared with clopidogrel.(continued on page A-23)
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EALVULAR HEART DISEASE686Initial Results With the MitraClip Deviceed Feldman, Saibal Kar, Michael Rinaldi, Peter Fail, James Hermiller, Richard Smalling,
atrick L. Whitlow, William Gray, Reginald Low, Howard C. Herrmann, Scott Lim, Elyse Foster,
onald Glower, for the EVEREST Investigators
he MitraClip device (Evalve Inc., Menlo Park, California) is designed to reduce mitral
egurgitation (MR) by creating a double orifice by connecting the central portion of the 2
eaflets with a metal clip. Feldman and colleagues describe the safety and midterm efficacy
esults of over 100 patients treated with the device. Ten patients (9%) had a major adverse
vent, including a single death. There were no incidences of clip embolization, although the
lip did detach from a single leaflet in 9% of subjects. Overall acute procedural success was
6%, with most of these patients having 1 or less MR. For the subjects who subsequently
equired open surgery after a clip procedure, there was no evidence that the procedure made
he valve “nonrepairable.” Percutaneous repair with the MitraClip appears promising with low
orbidity and mortality.RTERIAL REFLECTIONS AND STIFFNESS695Increased Pulse Pressure Caused by Increased Wave Reflections in Womenarina Cecelja, Benyu Jiang, Karen McNeill, Bernet Kato, James Ritter, Tim Spector, Phil Chowienczyk
entral pulse pressure (cPP) is augmented above the first systolic shoulder of the central
rterial pulse (P1) by pressure waves reflected from the periphery of the circulation. Cecelja
nd colleagues sought to determine the relative contributions of P1 and the augmentation
ressure (Paug) to cPP, and the causes of higher Paug in women. P1 and Paug
ccounted for 22% and 76%, respectively, of the variance in cPP. P1 was positively correlated
ith pulse wave velocity, whereas Paug was negatively correlated with the ratio of the
iameter of the femoral artery to that of the abdominal aorta. These results suggest that, in
omen, Paug is the major determinant of cPP and might be caused by relatively small
emoral arteries.RTERIAL REFLECTIONS AND STIFFNESS
705low Heart Rates Increase Pressure
Reflection Waves, Increase Central Aortic Pressureryan Williams, Peter S. Lacy, for the CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes
rial) Investigators
his analysis sought to determine why atenolol was less effective at reducing cardiovascular
vents compared with an amlodipine-based regimen. Central pressures were derived from
rachial pressure and radial pulse wave analysis in over 2,000 subjects with more than 7,000
easurements over 4 years. There was no impact of heart rate on brachial systolic or brachial
ulse pressures; however, slower heart rates did correlate with higher central aortic systolic
nd central pulse pressures. Further analysis showed a strong inverse relationship between
eart rate and augmentation index, suggesting increased wave reflection at lower heart rates.
hese findings indicate that heart rate reduction with beta-blockers is a major mechanism
ccounting for less effective central aortic pressure reduction per unit change in brachial pressure.ditorial Comment: Michael F. O’Rourke, Christopher S. Hayward, p. 714
(continued on page A-24)
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EBESITY AND THE HEART718Weight Loss Decreases LV Mass, Improves Filling Parametersliver J. Rider, Jane M. Francis, Mohammed K. Ali, Steffen E. Petersen, Monique Robinson,
atthew D. Robson, James P. Byrne, Kieran Clarke, Stefan Neubauer
bese patients have higher rates of left ventricular hypertrophy (LVH), but it is not clear if
he LVH results solely from obesity or from related conditions, such as hypertension,
iabetes, or hypercholesterolemia. Rider and colleagues studied the effects of substantial
eight loss over 1 year in obese subjects without other risk factors for LVH. Thirty-seven
bese (body mass index 40 kg/m2) and 20 normal-weight subjects underwent cardiac
agnetic resonance imaging. Thirty of the obese subjects underwent repeat imaging after 1
ear of significant weight loss, achieved by diet or bariatric surgery. Left ventricular (LV) and
ight ventricular mass were significantly increased in the obese; LV diastolic function and
ortic distensibility were also impaired. Both diet and bariatric surgery led to comparable
mprovements in these parameters. LVH can be caused solely by obesity and can regress with
eight loss.ditorial Comment: Elie Mousseaux, p. 727EDIATRIC CARDIOLOGY
730xtracorporeal Membrane Oxygenation Is Effective
for Early Failure After Pediatric Heart Transplantationecile Tissot, Shannon Buckvold, Christina M. Phelps, D. Dunbar Ivy, David N. Campbell,
ax B. Mitchell, Suzanne Osorio da Cruz, Bill A. Pietra, Shelley D. Miyamoto
his paper describes the use of extracorporeal membrane oxygenation (ECMO) to support
ediatric patients who either fail to wean from cardiopulmonary bypass after heart
ransplantation or develop hemodynamic instability within the first few days after
ransplantation. Tissot and colleagues reviewed the records of over 300 patients who
nderwent transplantation, of whom 28 (9%) required ECMO. The median age was 0.3
ears and the median weight was 4.5 kg. Approximately one-half of patients were successfully
eaned off of ECMO and discharged alive, with a mean duration of ECMO of 2.8 days for
urvivors. Of the patients who survived the index hospitalization, 100% were alive 3 years
ater. ECMO appears to be useful by providing temporary support in the immediate post-
perative period after pediatric heart transplantation.ditorial Comment: Carl Lewis Backer, p. 738
